Benzinga · Sep 4, 2026
BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price Target
BTIG analyst Mark Massaro reiterates Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and maintains $5 price target.
NYSE · DNA
Healthcare · Biotechnology
$6.75
Down-$0.03 (-0.44%)
Updated Sep 12, 2026, 12:34 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DNA closed at $6.75 after 20 trading sessions, down 0.59% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $6.80 | $6.83 | $6.52 | $6.75 | 932.66K |
| Sep 10, 2026 | $6.72 | $6.85 | $6.59 | $6.78 | 679.47K |
| Sep 9, 2026 | $6.83 | $6.93 | $6.72 | $6.79 | 894.18K |
| Sep 8, 2026 | $7.00 | $7.06 | $6.75 | $6.94 | 1.08M |
| Sep 4, 2026 | $6.80 | $6.97 | $6.74 | $6.95 | 656.66K |
| Sep 3, 2026 | $7.16 | $7.22 | $6.76 | $6.95 | 860.36K |
| Sep 2, 2026 | $6.92 | $7.2986 | $6.77 | $7.03 | 1.27M |
| Sep 1, 2026 | $6.66 | $6.985 | $6.62 | $6.93 | 1.81M |
| Aug 31, 2026 | $6.90 | $6.96 | $6.67 | $6.81 | 1.21M |
| Aug 28, 2026 | $7.23 | $7.285 | $6.91 | $6.96 | 1.26M |
| Aug 27, 2026 | $7.34 | $7.43 | $7.17 | $7.26 | 757.66K |
| Aug 26, 2026 | $7.33 | $7.47 | $7.19 | $7.23 | 628.79K |
| Aug 25, 2026 | $6.94 | $7.63 | $6.86 | $7.54 | 1.68M |
| Aug 24, 2026 | $7.25 | $7.305 | $6.75 | $6.78 | 1.08M |
| Aug 21, 2026 | $7.09 | $7.42 | $6.82 | $7.40 | 1.44M |
| Aug 20, 2026 | $7.45 | $7.645 | $6.925 | $6.96 | 1.42M |
| Aug 19, 2026 | $6.98 | $7.7485 | $6.95 | $7.71 | 2.47M |
| Aug 18, 2026 | $6.72 | $6.875 | $6.47 | $6.53 | 1.12M |
| Aug 17, 2026 | $6.70 | $6.99 | $6.62 | $6.92 | 690.13K |
| Aug 14, 2026 | $7.20 | $7.20 | $6.775 | $6.79 | 1.45M |
The latest Smart Investors Daily articles mentioning DNA.
DNA research
Company profile and research snapshot.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | BTIG | Sell | — |
| Aug 7, 2026 | TD Cowen | Hold | — |
| Mar 12, 2026 | BTIG | Sell | — |
| Jan 8, 2026 | TD Cowen | Buy | — |
| Aug 25, 2025 | BTIG | Sell | — |
No generated briefing is available yet.
Benzinga · Sep 4, 2026
BTIG analyst Mark Massaro reiterates Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and maintains $5 price target.
SeekingAlpha · Sep 1, 2026
Ginkgo Bioworks has pivoted to autonomous lab infrastructure in an attempt to capitalize on emerging AI tailwinds. Read more on DNA stock here.
Fintel · Aug 8, 2026
Benzinga · Aug 7, 2026
TD Cowen analyst Brendan Smith downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Hold and lowers the price target from $12 to $9.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning DNA.